FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
- Follicle-stimulating hormone (FSH) has been indicated in the development and progression of prostate cancer.
- Coupled with testosterone suppression to castration levels, FSH suppression may delay disease progression, and improve prognosis.
- Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist, has been associated with rapid and profound testosterone and FSH suppression along with prostate specific antigen (PSA) suppression.
- Here we present the factors predicting the FSH suppression including ′on treatment′ PSA suppression from an already published study.